# WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITE

> **NIH CA UG1** · WASHINGTON UNIVERSITY · 2026 · $1,612,916

## Abstract

Project Summary
The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead
Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate
in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual
to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare
cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative
group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical
Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 4 UG1 co-
Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor,
Medical Oncology), Premal Thaker, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Professor,
Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is
composed of four legacy members with extensive cooperative group and NCTN experience (Bartlett, Thaker,
Robinson and Siegel). We feel this consistency will bring continued success to the NCTN program. The entire
leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has
consistently demonstrated robust accrual to NCTN trials, accruing 1217 patients between March 2019 and
August 2024. During this same interval, 764 patients had biospecimens collected and 32 patients were
accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular
imaging programs in combination with the large institutional biorepositories position us to make significant and
novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in
NCTN translational and clinical research in AML, lymphoma, lung cancer, breas

## Key facts

- **NIH application ID:** 11289863
- **Project number:** 2UG1CA233339-07
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** NANCY L BARTLETT; Clifford Grant Robinson; BARRY A. SIEGEL; Premal Harish Thaker
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $1,612,916
- **Award type:** 2
- **Project period:** 2019-03-05T00:00:00 → 2032-02-29T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11289863

## Citation

> US National Institutes of Health, RePORTER application 11289863, WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITE (2UG1CA233339-07). Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/grant/nih/11289863. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*